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Introduction: Pharmacokinetic (PK) studies on recombinant FIX concentrate, Nonacog alpha, were conducted
with different sampling time designs which gave rise to not complete and homogenous outcomes. In addition,
patient’s FIX genotype/PK relationship has never been investigated. Aim: Investigate how different sampling
times may affect PK parameters and try to find a FIX genotype/PK relationship. Patients and Methods: A cohort
pharmacokinetic, Nonacog Alpha single-dose, open-label, non-comparative study was conducted in eight
Comprehensive Care Haemophilia Centres in Italy. Seventeen previously treated moderate or severe haemophilia
B patients were enrolled. Factors IX:C one-stage clotting assay, FIX genotype and PK analysis were centralized.
Results: The evaluation of PK outcomes showed a quite long half-life, smaller clearance and volume of
distribution of Nonacog Alpha in comparison with the results from previously reported studies, where blood
sampling was stopped too early. The relationship between PK outcomes and FIX genotype showed that small
deletions displayed the higher clearance and shorter half-life, the nonsense mutations (the lower and the longer
respectively), and missense mutations were in between. Conclusions: It is evident that area under the curve
(AUC) and other PK parameters depend from the sampling time design. In order to have a complete evaluation
of clotting factors in vivo decay, blood samples must be collected until the baseline factor concentration has been
achieved again. Due to the relationship between FIX genotype and clearance, tailored prophylaxis of HB patients
could be partially predicted by genotyping.
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Introduction
Very few well-designed studies have been conducted
to achieve complete information about the PK of
rDNA derived factor IX concentrate, Nonacog Alpha,
in haemophilia B patients. In some studies, the sam-
pling times or PK analysis were not adequate, some-
times limited to 48th hour, sometimes extended to
72nd hour. In addition, the FIX genotype of patients
was never reported.
Nonacog Alpha (BeneFixTM, Pfizer Inc, New York,
NY, USA), recombinant coagulation factor IX, is a
415-amino acid glycoprotein (approximately 55k.Da)
produced in Chinese hamster ovary (CHO) cells. It
belongs to the so called ‘Third generation recombi-
nant concentrates’ because the medium where the
cells grow and the final formulation do not contain
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any animal or human protein. After two steps of
purification by ion exchange and affinity chromatog-
raphy, Nonacog alpha is submitted to nanofiltration
(20 nm pores) in order to remove any pathogens,
eventually present in the cell culture. The first article
[1] published in 1997 was a report of the regulatory
bioequivalence study conducted in a small cohort of
patients (n = 11) comparing Nonacog alpha against a
monoclonal plasma-derived FIX (pdFIX) concentrate.
Only in vivo recovery (IVR), half-life (HL) and mean
residence time (MRT) were reported. Another cross-
over study confirmed the low IVR of Benefix with
respect to pdFIX even though HL was similar in both
products [2]. A well-designed study on a large cohort
of patients (n = 56) conducted at the switch from
pdFIX concentrate to Nonacog alpha reported again
similar outcomes, but again limited to IVR and HL
[3]. The raw data of another previously published
study [4] were afterwards analysed by S. Bjorkman in
order to determine the standard pharmacokinetic
parameters according to a one- and two-open com-
partment model: for the first time, also clearance
(Cl), volume of distribution at steady state (Vdss),
and terminal half-life (t1/2) were published further
than IVR and MRT [5]. A new double-blind, ran-
domized, pharmacokinetic crossover study involved
the new reformulated Nonacog alpha in comparison
with the original Nonacog Alpha [6]. Analysis of
AUC, both percentage as well as incremental IVR,
and terminal half-life did not show any difference
between the two formulations. Most of these studies
have been conducted with different and sometimes
inadequate study designs. Only the analysis per-
formed by S. Bjorkman [5] provided a complete
report of all the PK parameters needed for a good
evaluation of Nonacog alpha. For these reasons, we
planned to conduct in Italy a multicentre PK study
designed according to the ISTH recommendations
[7,8], taking into account also the FIX genotype of
each patient.
The primary objective of the study was to investi-
gate the variability in all PK parameters (in vivo
recovery, AUC, clearance, MRT, elimination rate con-
stant, volume of distribution, terminal half-life of
Nonacog alpha and the correlation between FIX geno-
type and PK outcomes, in severe and moderate hae-
mophilia B previously treated patients. The secondary
objective was to evaluate different methods of PK
analysis.
Patients and methods
Single-dose PK was performed in eight Comprehensive
Care Haemophilia Centres (HCC) of Italy. Seventeen
moderate and severe haemophilia B patients have been
enrolled in the study. PK study was performed accord-
ing to the ISTH recommendations: after a wash out of
at least 7 days, a single dose, 47.70  4.13 IU kg1
b.w., of Nonacog alpha was injected in less than
10 min and blood samples were collected just before
the infusion (baseline FIX concentration) and 0.25, 1,
3, 9, 24, 48, and 72 h after the end of infusion. Three
aliquots of platelet poor citrated plasma of each sam-
ple were snap frozen and stored at 80°C. The sam-
ples were shipped within 30 days, in dry ice to the
central laboratory located in the Haemophilia Centre
of Florence. FIX:C was assayed by means of one-stage
clotting method, performed by means of coagulometer
Behring Coagulation Time (BCT) of Siemens Health-
care Diagnostics using three double dilutions of each
sample compared with a reference curve of standard
human plasma (Siemens Healthcare GmbH, Erlangen,
Germany). FIX inhibitor was assayed on the baseline
sample, according to Nijmegen method. FIX genotype
was performed on whole blood samples at Hae-
mophilia Centre of Castelfranco Veneto by means of
Conformation Sensitive Gel Electrophoresis (CSGE)
[9], a rapid non-radioactive heteroduplex-based
method, followed by sequencing of the purified gene
fragment suspected to contain the molecular defect.
Comparison with the wild type is performed using the
BLAST software, which is developed and maintained
by a group at the National Centre for Biotechnology
Information (NCBI;www.ncbi.nlm.nih.gov).
The study was approved by the Ethical Committee
of Coordinator Centre and by each of other HCC
(EudraCT n. 2008-006465-85). It was planned to
enrol about 50 HB patients, but unfortunately, many
patients denied undergoing such demanding protocol.
We decided to stop the study after 5 years when only
17 patients agreed to participate to this study.
Pharmacokinetic analysis
PK analysis was conducted by means of Phoenix
WinNonlin 6.3 software (Certara USA Inc., Princeton,
NJ, USA). Non-compartmental analysis (NCA), one-
and two-compartment methods (OCM and TCM)
were used to evaluate the behaviour of infused Nona-
cog alpha and to compare these outcomes with FIX
genotype of patients. The baseline FIX:C concentra-
tion has been subtracted from each postinfusion con-
centration of PK.
The parameters reported on Table 1 (Elimination
rate constant, IVR, Terminal Half-life, AUC, Clear-
ance, MRT, and Volume of distributions) have been
calculated by means of NCA. In addition, OCM and
TCM provided K1-0, i.e. the elimination rate constant
from central compartment and the corresponding half-
life (K1-0_HL). TCM also provided the alpha elimina-
tion rate constant associated with the distribution
phase and beta elimination rate constant associated
with the elimination phase and their respective half-
lives. In order to evaluate which compartmental model
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fits better the PK data, we calculated the sum of
squared residuals (SSR) according to OCM and TCM.
We assumed that the model best fitting the observed
data was that with the smaller SSR. Incremental
recovery was calculated as ratio between the FIX:C
peak (IU dL1) and dose kg1 (IU kg1), according to
Prowse [10].
Results
The means and 1 SD of each PK outcomes are
reported on Tables 1 and 2. The average age of
patients was 34.5 years (range: 15.4–60.6 years), and
weight average was 74.0 kg (range: 50.0–110.0 kg).
The average FIX:C at baseline was 1.2 IU dL1
(range: 0.1–5.1 IU dL1) and FIX inhibitor was
0.04 BU mL1 (range: 0.00–0.10 BU mL1). Table 1
reports the outcomes of PK analysis, as far as NCA
and TCM methods are concerned. A very good corre-
lation between times and rFIX concentration has been
shown by the high values of adjusted R2, according to
NCA. This is the reason to evaluate the elimination
constant rate and terminal half-life by NCA; the linear
regression analysis was performed by WinNonlin on
about all postinfusion points (generally six out of
seven). The average terminal half-life resulted near
30 h, but in seven out of 17 patients was longer than
30 h. In addition, OCM and TCM confirmed these
values, both MRT as well as HL, even though the HL
according to the elimination rate from the central
plasma compartment (K1-0 HL) of both models were
lower, 20.64 and 22.30 h respectively. Nevertheless,
the beta elimination HL by TCM (38.35 h) was very
similar to MRTinf of NCA (42.12 h). Very long MRT
resulted also by TCM, i.e. 49.58 h. The trough level
of rFIX at 72 h was still high; mean 7.7 IU dL1 (3–
15 IU dL1). This observation has been confirmed by
the high percentage (18.6%) of extrapolated AUC to
infinity. The clearance and volume of distribution at
steady state of Nanacog alpha normalized by
patients’ body weight resulted 3.09 mL h1 kg1 and
111.1 mL kg1 respectively. A paired t Student test
comparing the outcomes of OCM and TCM showed
statistically significant difference (P < 0.001) between
the two models, as far as AUC, AUMC, Cmax, Cl,
MRT and Vss are concerned (data not shown). The
statistically significant smaller SSR achieved by TCM
with respect to OCM (45.26 vs. 143.23, P < 0.001)
shows that TCM fits the Nonacog alpha PK data
better than OCM. The range of incremental IVR
was 0.89–2.23 IU dL1 IU1 kg1; the mean being
1.22 IU1 dL1 IU1 kg1
(1.14 IU1 dL1 IU1 kg1, short of the highest
value).
All genotypes observed in our cohort were classified
into three groups: 1 – Small base deletion (SBD,
n = 2); 2 – Missense mutation (MM, n = 10); 3 –
Nonsense mutation (NM, n = 3). Due to the small
size of these groups, we reported in Table 2 only the
ranges of each PK outcome observed. According to
NCA, both patients of the first group displayed the
shortest terminal half-life or MRT, and the higher
clearance with respect to the all other patients. On the
contrary, the longest terminal half-life and the smaller
clearance was observed in the three patients of group
3, even though a partial overlap with patients of
group 2 was reported. Cmax, IVR, AUC, and Vss
were randomly distributed among the three groups.
Even though TCM resulted more accurate than OCM
because of its definitively reduced SSR (data not
shown), beta HL, clearance and MRT according to
TCM did show less significant clustering of outcomes
within the genotypes as observed by NCA. A sum-
mary of these data are reported in Fig. 1. Among the
outcomes of TCM, a good correlation has been
observed between MRT and beta HL (R2 = 0.97,
P < 0.01), as well as between terminal half-life and
MRT evaluated by NCA (R2 = 0.61, P < 0.02). Both
Clearance from NCA and TCM were well correlated
(R2 = 0.80, P < 0.01). On the contrary, no correla-
tions have been found in our study between MRT by
NCA and by TCM, neither between IVR and Vss nor
between terminal half-life by NCA and beta HL by
TCM.
Table 1. Non-Compartment and Two-Compartment Analysis of Nona-
cog alpha pharmacokinetics.







Squared R adjusted R2 0.977535 0.02166
Elimination constant rate 1 h1 0.033224 0.030618
Terminal Half-life Hours 29.81 13.22987
Peak U dL1 57.52 14.9
Trough U dL1 7.71 4.15
AUC observed, last point U*h dL1 1442.58 426.33
AUC observed, infinity U*h dL1 1835.78 672.12
Clearance mL h1 228.30 147.0
Clearance normalized by BW mL h1
kg1
3.01 1.35
MRT observed, last point Hours 23.76 3.51
MRT observed, infinity Hours 42.12 15.07
Half-life according to MRT Hours 29.19 10.44
Volume of distribution (Vd)
according to terminal
half-life, normalized by BW
mL kg1 110.46 30.78
Volume of distribution (Vss)
at steady state,
normalized by BW
mL kg1 111.1 22.66
Two-compartment model
AUC U*h dL1 1950.15 649.50
K10 Half-life Hours 22.30 8.04
Alpha, Distribution Half-life Hours 4.50 4.43
Beta, Elimination Half-life Hours 38.35 23.10
Cmax IU dL1 63.52 21.11






MRT Hours 49.58 23.71
Vss normalized by BW mL kg1 121.59 56.09
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Discussion
The figure of IVR is a bit higher than that,
0.78  0.24 or 0.86  0.21 IU1 dL1 IU1 kg1,
reported by first studies [1,2], confirmed also after the
Nonacog alpha reformulation of diluent (0.73  0.20
IU1 dL1 IU1 kg1) [6]. Very recently, higher val-
ues of IVR of Nonacog alpha, 0.93  0.31 IU1
dL1 IU1 kg1, have been reported by L.A. Valen-
tino [11] and a very similar figure to our IVR by T.
Andreeva at ASH Annual Meeting 2015: 1.24  0.32
IU1 dL1 IU1 kg1 [12]. These changes of Nonacog
alpha concentrate IVR during the last years might
reflect some changes in the manufacturing procedures
or of the labelled potency.
An accurate and comprehensive PK analysis accord-
ing to three methods (NCA, OCM and TCM) was
able to characterize the Nonacog alpha in vivo beha-
viour better than in previous studies. The timing of
sample collection is crucial to achieve outcomes that
are more reliable. Even though the ISTH recommen-
dation stated for PK of FIX concentrate that the last
point could be the 72 h, more than 18% of AUC was
lost in this study, due to very high trough of decay
curve. Unfortunately, none PK studies respected the
golden rule of pharmacokinetics that sample collection
must be continued up to the baseline is again
achieved. On the other hand, it is difficult to forecast
a priori the time of next achieved baseline. Also in
our study, the range of trough was high. In all recent
published comparative studies between new long-act-
ing rFIX and Nonacog alpha, the sampling time of the
comparators, pdFIX and Nonacog alpha, has been
stopped too early, generally at 48 h after the end of
infusion [13–15]. This is the reason why lower values
of AUC, higher clearance and shorter half-life have
been reported with respect to the outcomes of our
study. On the contrary, when the sampling time was
Table 2. PK outcomes by NCA and TCM according to HB patients’ genotype.
Non-compartment analysis Two-compartment method
Terminal HL Cmax AUC MRT Cl Vss Beta_HL CL MRT
Hours IU dL1 U*h dl1 Hours mL h1 kg1 mL kg1 Hours mL h1 kg1 Hours
Small base deletion n = 2
Min 5.02 47.7 673 15.57 4.17 76 19.04 2.64 27.14
Max 9.69 59.3 1227 18.08 6.73 106 30.14 3.22 41.72
Missense mutation n = 10
Min 14.17 41.2 812 17.69 1.51 75 20.01 1.26 26.34
Max 42.20 106.3 2393 27.27 5.22 134 105.65 3.25 108.85
Nonsense mutation n = 3
Min 33.84 52.0 1420 25.17 1.63 98 34.60 1.07 46.73
Max 57.45 64.2 2060 26.76 2.76 162 78.89 2.08 95.92
Fig. 1. Terminal half-life, MRT and clearance according to NCA; MRT and beta half-life according to TCM.
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prolonged up to 72 h [16–18], the PK outcomes
resulted very similar to ours. The average values of all
clearances observed in our study resulted 50% less
than those reported in previous comparative studies of
N9-GP or rFIX-FP [14,15] because of different AUC.
The clearance observed in this study is similar to that
of rFIX-Fc [17]. In addition, the Vss was quite small
compared with the large Vss of rFIX-Fc, whose mean
value was 250 mL kg1 [19]. The large Vss of rFIX-
Fc is probably due to its uptake by Fc receptor bear-
ing cells.
Even though the size of this study is small, due to
the difficulties to enrol HB patients in such a demand-
ing protocol, the relationship between genotype and
PK outcomes resulted quite interesting. Patients with
SBD and with NM showed an opposite behaviour as
far as terminal half-life, clearance, MRT and beta
half-life were concerned. Outcomes of NCA seems to
be able to better discriminate differences among the
three groups of genotype. NCA is confirmed to be the
most robust and reliable method of analysis of PK
data because it is not affected by variance and errors
of fitting procedure of all compartment methods.
Model-independent method is more reliable than com-
partment methods both for FVIII and FIX concen-
trates, as our working group stated many years ago
[20,21]. OCM resulted definitely less accurate than
TCM because of its higher SSR. TCM seems to fit bet-
ter the PK data of rFIX, as also recently reported [22].
We would like to recommend that the choice of the
best fitting compartment method should be based on
SSR.
Conclusion
The analysis of single-dose PK multicentre study
showed different results from those previously
published because of different sampling times. Even
though the last sample was collected 72 h after the
end of infusion, 18% of Nonacog Alpha AUC was
lost. Clearance resulted about 50% less of that
reported in studies where the sampling was stopped at
48 h. Higher values of terminal half-life, MRT and
beta half-life have been observed by NCA or TCM.
TCM fitted very well the PK data as shown by the
very low SSR. Two patients with SBD displayed the
shortest terminal half-life and the higher clearance
than those with MM or NM. Due to the relationship
between FIX genotype and clearance, tailored prophy-
laxis of HB patients can be partially predicted by
genotyping.
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